American Journal of Obstetrics & Gynecology
Volume 186, Issue 5 , Pages 978-983 , May 2002

Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception

Received 16 August 2001 ,Revised 26 November 2001 ,Accepted 20 December 2001.

References 

  1. Ortiz A, Hiroi F, Stanczyk FZ, Goebelsmann V, Mishell DR. Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA. J Clin Endocrinol Metab. 1977;44:32–38
  2. Jeppsson S, Gershagen S, Johansson EDB, Rannevik G. Serum medroxyprogesterone (MPA), sex hormone binding globulin, gonadal steroids, gonadotropins and prolactin in women during long term use of depo-MPA as a contraceptive. Acta Endocrinol. 1982;99:339–343
  3. Cundy T, Evans M, Roberts H, Wattie D, Ames R, Reid IR. Bone density in women receiving depot medroxyprogesterone acetate contraception. Br Med J. 1991;303:13–16
  4. Gbolade B, Ellis S, Murby B, Randall S, Kirkman R. Bone density in long term users of depot medroxyprogesterone acetate. Br J Obstet Gynaecol. 1998;105:790–794
  5. Cundy T, Cornish J, Roberts H, Elder H, Reid IR. Spinal bone density in women using depot medroxyprogesterone contraception. Obstet Gynecol. 1998;92:569–573
  6. Paiva LC, Pinto-Neto AM, Faundes A. Bone density amongst long term users of medroxyprogesterone acetate as a contraceptive. Contraception. 1998;58:351–355
  7. Scholes D, Lacroix AZ, Ott SM, Ichikawa LE, Barlow WE. Bone mineral density in women using depot medroxyprogesterone for contraception. Obstet Gynecol. 1999;93:233–238
  8. Tang OS, Tang G, Yip P, Li B, Fan S. Long-term depot medroxyprogesterone acetate and bone mineral density. Contraception. 1999;59:25–29
  9. Cromer BA, Blair JM, Mahan JD, Zibners L, Naumovski Z. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr. 1996;129:671–676
  10. Angus RM, Sambrook PN, Pocock NA, Eisman JA. A simple method of assessing calcium intake in Caucasian women. J Am Diet Assoc. 1989;89:209–214
  11. Wilson PWF, Paffenberger RS, Morris JN, Harlik RJ. Assessment methods for physical activity and physical fitness in population studies. Am Heart J. 1986;111:1177–1192
  12. Recker R, Lappe J, Davies K, Heaney R. Characterization of perimenopausal bone loss. J Bone Miner Res. 2000;15:1965–1973
  13. Clark MK, Sowers M, Levy BT, Tenhundfeld P. Magnitude and variability of sequential estradiol and progesterone concentrations in women using depot medroxyprogesterone acetate for contraception. Fertil Steril. 2001;75:179–185
  14. Carter DR, Bouxsein ML, Marcus R. New approaches for interpreting projected bone densitometry data. J Bone Miner Res. 1992;7:137–145
  15. Cundy T, Cornish J, Evans MC, Roberts H, Reid IR. Recovery of bone density in women who stop using medroxyprogesterone acetate. BMJ. 1994;308:247–248
  16. Orr-Walker BJ, Evans MC, Ames RW, Clearwater JM, Cundy T, Reid IR. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal postmenopausal women. Clin Endocrinol. 1998;49:615–618
  17. Grey AB, Cundy TF, Reid IR. Combined continuous oestrogen/progestin therapy is well tolerated and increases bone density at the hip and lumbar spine in post-menopausal osteoporosis. Clin Endocrinol. 1994;40:671–677
  18. Ott SM, Scholes D, Lacroix AZ, Ichikawa LE, Yoshida CK, Barlow WE. Effects of contraceptive use on biochemical markers in young women. J Clin Endocrinol Metab. 2001;86:179–185

☆ Supported by the Health Research Council of New Zealand.

☆☆ Reprint requests: Tim Cundy, MD, Department of Medicine, 4th Floor, Auckland Hospital, Private Bag 92-019, Auckland, New Zealand. E-mail: t.cundy@auckland.ac.nz

PII: S0002-9378(02)85159-6

doi: 10.1067/mob.2002.122420

American Journal of Obstetrics & Gynecology
Volume 186, Issue 5 , Pages 978-983 , May 2002

Article Tools

* Image Usage & Resolution